Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

2.9%

1 terminated/withdrawn out of 34 trials

Success Rate

96.6%

+10.1% vs industry average

Late-Stage Pipeline

41%

14 trials in Phase 3/4

Results Transparency

29%

8 of 28 completed trials have results

Key Signals

3 recruiting8 with results

Enrollment Performance

Analytics

Phase 4
14(82.4%)
N/A
2(11.8%)
Phase 1
1(5.9%)
17Total
Phase 4(14)
N/A(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (34)

Showing 20 of 34 trials
NCT06964113Phase 4Recruiting

A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

Role: lead

NCT06810960Recruiting

A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

Role: lead

NCT06625242Phase 4Active Not Recruiting

A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis

Role: lead

NCT05225324Completed

A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)

Role: lead

NCT06246123Recruiting

A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

Role: lead

NCT05533814Phase 4Completed

A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures

Role: lead

NCT05312632Phase 4Completed

A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Role: lead

NCT05375136Completed

A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients

Role: lead

NCT05225207Completed

A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants

Role: lead

NCT05208268Completed

A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer

Role: lead

NCT05366036Completed

A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis

Role: lead

NCT00381381Phase 4Completed

The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease

Role: lead

NCT01140867Phase 4Completed

Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy

Role: lead

NCT01127256Phase 4Completed

Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation

Role: lead

NCT00165724Phase 4Completed

Alzheimer's Disease Long-term Follow-up Study (ALF Study)

Role: lead

NCT02764554Completed

Post-Marketing Surveillance of Lenvima in Korean Patients

Role: lead

NCT03448445Completed

A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting

Role: lead

NCT04061863Phase 1Unknown

Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer

Role: collaborator

NCT02722590Completed

A Study of Fycompa (Perampanel) in Korean Participants

Role: lead

NCT02434484Completed

Symbenda Post-Marketing Surveillance (PMS)

Role: lead